Dr. Nedal Bukhari

Consultant Medical Oncologist; Director, Medical Oncology Fellowship Program

Dr. Nedal Bukhari is a highly accomplished Saudi Consultant Medical Oncologist based in Riyadh, currently serving as the Director of the Medical Oncology Fellowship Training Program at Prince Sultan Military Medical City (PSMMC). He is widely recognized for his clinical leadership in managing solid tumors and his commitment to medical education within the Kingdom.

Current Roles & Leadership
• Fellowship Director: Leads the training and development of future specialists as the Director of the Medical Oncology Fellowship Program at Prince Sultan Military Medical City.
• Committee Chair: Serves as the Head of the Coaching and Advice Committee within the Oncology Department at PSMMC.
• Clinical Consultant: Provides advanced clinical oncology care for adult solid tumor patients at Prince Sultan Military Medical City.

Credentials & Board Certifications
Dr. Bukhari holds an impressive portfolio of international medical credentials, fellowships, and academic degrees:
• Medical Degree: Completed his MBBS in Saudi Arabia.
• North American Certifications: Fellow of the Royal College of Physicians of Canada—FRCP(C)—and Diplomate of the American Board of Internal Medicine—DABIM.
• Elite Memberships: Elected Fellow of the American College of Physicians (FACP) and Fellow of the Royal College of Physicians and Surgeons of Glasgow (FRCP Glasg).
• Executive Leadership: Holds an Executive Master of Business Administration (EMBA), bolstering his healthcare administrative leadership capabilities.
Specialization & Research Interests

Dr. Bukhari is highly active in clinical trial tracking, epidemiological mapping, and molecular tumor targeting:
• Genitourinary (GU) Cancers: Expert in the latest perioperative and advanced systemic treatment updates for bladder and prostate malignancies.
• Gastrointestinal (GI) Cancers: Focuses on managing aggressive abdominal malignancies, including evaluating specialized second-line chemotherapy lines for stage 4 pancreatic cancer.
Oncology Pharmacogenomics: Researches the utility of individualized tumor markers to predict systemic treatment responses and patient toxicity profiles.
Public Health Studies: Investigates regional clinical burdens, including studying the rising impact of obesity-linked cancers in Saudi Arabia and tracking the psychological well-being of oncology clinicians across the Middle East.